Heart failure & cardiomyopathies
Increased Acylcarnitines in Infant Heart Failure Indicate Fatty Acid Oxidation Inhibition: Towards Therapeutic Options?
Main finding · Total acylcarnitines (sum of C3 to C18 species)Result — go to the resultFold increase 3.1Authors' conclusion
Our results suggest down-regulation of fatty acid oxidation in children with heart failure.
Study context
- Population
- Children under 16 years old with dilated cardiomyopathy and clinical HF
- Comparison
- Children with DCM-HF vs control children
- DCM-HFn = Nine
- Controln = eightreference
- Outcome
- Acylcarnitine profiles on dried blood spots (fatty acid oxidation)
Main finding
Total acylcarnitines (sum of C3 to C18 species)
Fold increase
3.1
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Fold increase |
|---|---|
| Long-, medium- and short-chain acylcarnitinesDCM-HF vs Control · long-chain (C14 to C18) | 2.0 |
| Long-, medium- and short-chain acylcarnitinesDCM-HF vs Control · medium-chain (C8 to C12) | 2.6 |
| Long-, medium- and short-chain acylcarnitinesDCM-HF vs Control · short-chain (C3 to C6) | 1.9 |
Correlation of LV dilatation or EF with acylcarnitine accumulation
- Significant linear correlation
Acylcarnitine ratios C16OH/C16 and C18OH/C18
- Enhanced in DCM-HF, suggesting diminished long-chain hydroxyl acyl-CoA dehydrogenase activity
Original publication
Increased Acylcarnitines in Infant Heart Failure Indicate Fatty Acid Oxidation Inhibition: Towards Therapeutic Options? ESC Heart Fail. Published 23 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →